<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer&apos;s disease in Brazil</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Luciana</forename><forename type="middle">R</forename><surname>Da Silva</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Cid</forename><forename type="middle">M M</forename><surname>Vianna</surname></persName>
							<email>cdvianna@gmail.com</email>
						</author>
						<author>
							<persName><forename type="first">Gabriela</forename><forename type="middle">B G</forename><surname>Mosegui</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Instituto de Sau ´de da Comunidade</orgName>
								<orgName type="institution">Universidade Federal Fluminense (UFF)</orgName>
								<address>
									<addrLine>Nitero ´i</addrLine>
									<region>RJ</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anto</forename><surname>ˆnio</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Peregrino</surname></persName>
							<affiliation key="aff2">
								<orgName type="laboratory">Laborato ´rio de Cie ˆncias Radiolo ´gicas (IBRAG)</orgName>
								<orgName type="institution">UERJ</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<region>RJ</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Valeska</forename><surname>Marinho</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Instituto de Psiquiatria</orgName>
								<orgName type="institution" key="instit2">UFRJ</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<region>RJ</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jerson</forename><surname>Laks</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Instituto de Psiquiatria</orgName>
								<orgName type="institution" key="instit2">UFRJ</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<region>RJ</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Programa de Biomedicina Translacional</orgName>
								<orgName type="institution" key="instit2">Universidade do Grande Rio (BioTrans-Unigranrio)</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<region>RJ</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">CMMV https://orcid</orgName>
								<address>
									<postCode>0000-0003-0252-1144</postCode>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="institution">GBGM https://orcid</orgName>
								<address>
									<postCode>0000-0001-5954-684X</postCode>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cid</forename><surname>Manso De Mello Vianna</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Instituto de Medicina Social</orgName>
								<orgName type="institution">Universidade do Estado do Rio de Janeiro (UERJ)</orgName>
								<address>
									<settlement>Rio de Janeiro</settlement>
									<region>RJ</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Instituto de Medicina Social</orgName>
								<orgName type="institution" key="instit1">Universidade do Estado do Rio de Janeiro (UERJ)</orgName>
								<orgName type="institution" key="instit2">Rua Sa ˜o Francisco Xavier</orgName>
								<address>
									<addrLine>7 o andar, bloco D, Maracana ˜</addrLine>
									<postCode>524, 7015, 20550-900</postCode>
									<settlement>sala, Rio de Janeiro</settlement>
									<region>CEP, RJ</region>
									<country key="BR">Brazil</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer&apos;s disease in Brazil</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">5B931DF8DF6F19F4AD759A5215747A1A</idno>
					<idno type="DOI">10.1590/1516-4446-2017-0021</idno>
					<note type="submission">Submitted Nov 12 2017, accepted Apr 23 2018, Epub Nov 08 2018.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:26+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Alzheimer&apos;s disease</term>
					<term>economic issues</term>
					<term>administration</term>
					<term>geriatric psychiatry</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objective: To perform a cost-effectiveness analysis of donepezil and rivastigmine therapy for mild and moderate Alzheimer's disease (AD) from the perspective of the Brazilian Unified Health System.</s><s>Methods: A hypothetical cohort of 1,000 individuals of both sexes, aged 465 years, and diagnosed with AD was simulated using a Markov model.</s><s>The time horizon was 10 years, with 1-year cycles.</s><s>A deterministic and probabilistic sensitivity analysis was performed.</s><s>Results: For mild AD, the study showed an increase in quality-adjusted life years (QALYs) of 0.61 QALY/21,907.38</s><s>Brazilian reais (BRL) for patients treated with donepezil and 0.58 QALY/BRL 24,683.33 for patients treated with rivastigmine.</s><s>In the moderate AD group, QALY increases of 0.05/ BRL 27,414.96</s><s>were observed for patients treated with donepezil and 0.06/BRL 34,222.96</s><s>for patients treated with rivastigmine.</s><s>Conclusions: The findings of this study contradict the standard of care for mild and moderate AD in Brazil, which is based on rivastigmine.</s><s>A pharmacological treatment option based on current Brazilian clinical practice guidelines for AD suggests that rivastigmine is less cost-effective (0.39 QALY/BRL 32,685.77)</s><s>than donepezil.</s><s>Probabilistic analysis indicates that donepezil is the most cost-effective treatment for mild and moderate AD.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Alzheimer's disease (AD) is a neurodegenerative disorder that causes dementia with gradual loss of cognitive function, leading to declines in social and functional activities of daily living.</s><s>4]<ref type="bibr" target="#b4">[5]</ref> In Brazil, the incidence of dementia ranges from 13.8 to 34.2 per 1,000 population/ year. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b5">6</ref></s><s>Despite the scarcity of further data on the prevalence and incidence of AD in Brazil, studies have reported incidence rates between 7.7 new cases/year in Sa ˜o Paulo to 14.8 new cases/year in Rio Grande do Sul. <ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b6">7</ref></s><s>he impacts of AD can be observed at different levels in society.</s><s>Disease progression and the consequent demential process cause loss not only of cognitive and functional abilities but also of quality of life.</s><s>In addition to the social impact, there is an economic impact caused by the care needs that result from AD progression. <ref type="bibr" target="#b7">8</ref></s><s>The economic burden of AD is also felt by governments, as the social cost of AD has risen to become one of its most significant chronic effects in recent decades. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b10">10</ref></s><s>o date, only two countries in Latin America have specific policies for dementia.</s><s>Bolivia approved Law No. 4034, Creacio ´n de Centros de Apoyo a Enfermos de Alzheimer y otras Demencias (Creation of Support Centers for Patients with Alzheimer and Other Dementias) in 2009, while Peru implemented Law No. 30020 in 2013, which establishes the Plan Nacional para la Enfermedad de Alzheimer y otras Demencias (National Plan for Alzheimer's Disease and other Dementias).</s><s>Despite pushes by the Pan American Health Organization (PAHO)/ WHO and ADI for the development of plans of action for mental health, the current Brazilian policy for dementia care is largely based on pharmacotherapy and compliance with the Brazilian Ministry of Health's corresponding clinical practice guideline (Protocolo Clı ´nico e Diretrizes Terape ˆuticas, PCDT). <ref type="bibr" target="#b11">11</ref></s><s>edications currently approved for the treatment of AD are still purely symptomatic, and produce only modest effects. <ref type="bibr" target="#b13">12</ref></s><s>Anticholinesterase agents are the mainstay of AD pharmacotherapy, and there is some evidence that they work to slow disease progression. <ref type="bibr" target="#b14">13</ref></s><s>Among these agents, donepezil, galantine, and rivastigmine are listed in the Brazilian PCDT.</s></p><p><s>In an analysis of anticholinesterase agent procurement data available through the Outpatient Information System (Sistema de Informac¸o ˜es Ambulatoriais, SIA) of the Brazilian Unified Health System, Lima &amp; Coradi 14 reported a 109% increase in expenditures over a 5-year period, from BRL 75.6 million in 2007 to BRL 157.8 million in 2011.</s><s>From 2008-2013, more than 47 million unit doses of these medicines were purchased, at a total cost exceeding BRL 90 million.</s><s>Rivastigmine, in its various dosage forms, was the most commonly used drug (46.4% of all purchases).</s><s>Drugs not indicated in the PCDT accounted for 3% of expenditures, with a negligible percentage of purchases <ref type="bibr" target="#b8">9</ref> occurring as the result of legal action.</s><s>The trend for increased donepezil purchasing continued until 2012, at which time a decline occurred.</s><s>Rivastigmine purchases presented a fluctuating trend in the period of analysis, with significant reductions in the volumes purchased in 2012 and 2013, when Productive Development Partnership (PDP) agreements were implemented. <ref type="bibr" target="#b8">9</ref></s><s>Given this context, to what extent can a costeffective AD care policy be sought from the standpoint of medications?</s></p><p><s>The objective of this work is to perform an analysis of the cost-effectiveness of donepezil and rivastigmine, the drugs most commonly prescribed for mild and moderate AD, <ref type="bibr" target="#b16">15</ref> from the perspective of the Unified Health System.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>A Markov chain simulation was used to carry out costeffectiveness analysis of pharmacological treatment strategies for AD.</s><s>Therapeutic scenarios for the treatment of AD were modeled according to the corresponding PCDT. <ref type="bibr" target="#b11">11</ref></s><s>The transition stages of the disease according to the Mini Mental State Examination (MMSE) <ref type="bibr" target="#b18">16</ref> were also included, with death as an absorptive stage (Figure <ref type="figure" target="#fig_0">1</ref>).</s></p><p><s>The Markov simulation model was calculated using TreeAge Pro ® software version 2011.</s><s>A hypothetical cohort of 1,000 individuals diagnosed with AD according to the PCDT criteria <ref type="bibr" target="#b11">11</ref> was considered.</s><s>The study population consisted of men and women aged 65 years and older -the age group with the highest incidence of AD, which is consistent with the natural history of the disease. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4,</ref><ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7</ref></s><s>he onset of the cycle was established with an initial distribution of subjects without the disease and patients with AD in the mild or moderate stages.</s><s>Transition probabilities were used recursively over time to simulate the progression of patients through the stages of illness.</s><s>Disease progression was established through MMSE scores for each stage in the three scenarios studied.</s></p><p><s>The treatment strategies being compared were pharmacotherapy with (1) donepezil 5 mg/day and 10 mg/day and (2) rivastigmine according to the PCDT dosage scheme (3 mg/day, 6 mg/day, and 9 mg/day).</s><s>As noted above, the proposed scenarios, as well as dose escalation procedures for both drugs, were based on the PCDT. <ref type="bibr" target="#b11">11</ref></s><s>8]<ref type="bibr" target="#b21">[19]</ref><ref type="bibr" target="#b22">[20]</ref><ref type="bibr" target="#b23">[21]</ref><ref type="bibr" target="#b24">[22]</ref><ref type="bibr" target="#b25">[23]</ref><ref type="bibr" target="#b26">[24]</ref> Three summative outcomes of AD were included in the simulation model, with probabilities were taken from national and international studies: a) depression and agitation <ref type="bibr" target="#b27">[25]</ref><ref type="bibr" target="#b28">[26]</ref><ref type="bibr" target="#b29">[27]</ref><ref type="bibr" target="#b32">[28]</ref><ref type="bibr" target="#b33">[29]</ref><ref type="bibr" target="#b34">[30]</ref> ; b) hospitalization for femoral fracture <ref type="bibr" target="#b35">[31]</ref><ref type="bibr" target="#b36">[32]</ref><ref type="bibr" target="#b37">[33]</ref> ; and c) pneumonia. <ref type="bibr" target="#b38">34</ref></s><s>he effectiveness of treatment was measured in qualityadjusted life years (QALYs). <ref type="bibr" target="#b19">17,</ref><ref type="bibr" target="#b20">18</ref></s><s>6]<ref type="bibr" target="#b42">[37]</ref><ref type="bibr" target="#b43">[38]</ref> The main outcomes used in the model are shown in Table <ref type="table" target="#tab_0">1</ref>.</s><s>The direct costs included in the study were those of the diagnostic tests recommended in the Brazilian AD PCDT <ref type="bibr" target="#b11">11</ref> (complete blood count, electrolytes, blood glucose, urea, creatinine, TSH, computed tomography and magnetic resonance imaging, neuropsychological tests) and pharmacological treatment (donepezil and rivastigmine).</s><s>Costs were evaluated from the perspective of the Brazilian health system and were accounted for in U.S. dollars and Brazilian reais (BRL).</s><s>Indirect costs were not considered.</s></p><p><s>The estimated drug cost was based on the mean unit price and duration of treatment.</s><s>Prices were obtained from the System of Management of the Table of Procedures and Medications (SIGTAP), for the year 2016, <ref type="bibr" target="#b45">40</ref> and the Federal Government Purchasing Portal (COM-PRASNET), for the years 2015/2016. <ref type="bibr" target="#b46">41</ref></s><s>For diagnostic tests, the reference date for SIGTAP values was December 2016.</s><s>The frequency and cost of tests were defined for: a) four annual medical appointments; b) hospitalization according to the prevalence of the outcomes of interest and treatment of the AD summative outcomes, i.e., medical conditions resulting from the disease; c) depression; d) pulmonary infection; and e) femoral fracture, which was included in the simulation because such fractures make treatment of AD more expensive and bring the model closer to reality.</s><s>These costs are represented in Table <ref type="table" target="#tab_3">2</ref>.</s></p><p><s>The perspective adopted was that of the SUS.</s><s>The comparative efficiencies of alternative treatment strategies were measured by the incremental cost-effectiveness ratio.</s><s>The discount rate was 5% per year for both costs and outcomes, and a sensitivity analysis was performed. <ref type="bibr" target="#b47">42</ref></s><s>he following assumptions were used in the simulation model: a) the probability of severity transition depended on the severity of the disease at the onset of treatment; b) the probability of death used in the model was set according to the stage of the disease; c) the model did not use the severe stage of AD in its analysis because the SUS does not offer treatment for this condition -i.e., Mild AD with NH 0.695 (0.021) Ikeda et al., <ref type="bibr" target="#b19">17</ref> Hartz et al., <ref type="bibr" target="#b44">39</ref> Jonsson et al., <ref type="bibr" target="#b42">37</ref> Naglie et al., <ref type="bibr" target="#b43">38</ref> Mesterton et al., <ref type="bibr" target="#b41">36</ref>  patients leave the model as they progress from moderate to severe AD; d) drug treatment does not alter disease mortality, but rather its progression to more severe stages; e) the 12-mg dose of rivastigmine was excluded in the model because of its restricted use in the public sector; and f) the cost of institutionalization was not included in the model due to the scarcity of cost information in the SUS databases.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>The Using a Markov model, we were able to simulate scenarios of treatment with donepezil and rivastigmine versus a baseline of untreated AD.</s><s>This simulation yielded the costs of pharmacological treatment and the overall cost of AD care, including the cost of the summative outcomes of the mild and moderate stages.</s><s>Moderate AD was the most costly phase of the disease, especially with rivastigmine treatment.</s><s>Compared with other drug interventions, the use of rivastigmine is less supported than treatment with donepezil, which has the best costeffectiveness ratio (Table <ref type="table" target="#tab_4">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sensitivity analysis</head><p><s>The sensitivity analysis aimed to test the robustness and results of the variations between the parameters used in the model.</s><s>Brazil does not have a formal threshold of acceptability for the incorporation of health technologies.</s><s>In this scenario, i.e., health systems that do not have a formal threshold, a value of three times the per capita gross domestic product (GDP) is recommended. <ref type="bibr" target="#b48">43</ref></s><s>For the year 2016, the value adopted was BRL 91,221/QALY; using this threshold, the likelihood of donepezil not being cost-effective was 2.8% when compared to rivastigmine (Figure <ref type="figure" target="#fig_1">2</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>In our analysis of overall AD treatment scores, there was a difference between letting the disease run its course (natural history) and administering anticholinesterase therapy, as well as between different stages of AD.</s><s>The cost of donepezil and rivastigmine treatment was lower than that of no treatment.</s><s>A similar finding was reported by Ikeda et al. <ref type="bibr" target="#b19">17</ref> Despite the similarity of the results, it is not possible to explain the difference in cost between pharmacological treatment and no treatment because the authors did not adequately discriminate among the costs of the resources used to calculate treatment.</s><s>Differences between costs were also observed in a study by <ref type="bibr">Hartz 39</ref> which evaluated donepezil and memantine at the more advanced stages of AD.</s></p><p><s>Regarding the effectiveness of the technologies for mild AD, the study reported a QALY increase of 0.61/BRL 21,907.38 for patients treated with donepezil and a QALY  The results of the present study are thus consistent with the international literature, where QALY gains in AD have been shown to be more significant in the mild phase of the disease than at the moderate stage. <ref type="bibr" target="#b19">17,</ref><ref type="bibr" target="#b21">19,</ref><ref type="bibr" target="#b24">22</ref></s><s>keda et al. <ref type="bibr" target="#b19">17</ref> conducted an economic evaluation of the use of donepezil (3 mg/day) in the treatment of mild and moderate AD in Japan.</s><s>Efficacy data were obtained from Japanese studies published in 1995 and 2000, and the unit costs of drugs were based on year-2000 prices.</s><s>A Markov model was simulated to characterize the progression of patients between the stages of AD.</s><s>At the mild stage, a QALY increase of 0.58/BRL 82,944.00 was observed, whereas at the moderate phase, the QALY increase was 0.31/BRL 148,716.00,</s><s>indicating donepezil is a cost-effective treatment for AD when compared to natural history of disease.</s><s>Neumann et al. <ref type="bibr" target="#b24">22</ref> conducted a cost-effectiveness analysis of the economic impact of donepezil treatment of mild and moderate AD in the United States.</s><s>The cost of donepezil was partially offset by the reduction in care costs related to improved cognitive function and delayed onset of the costlier stages of the disease.</s><s>The cost-effectiveness of donepezil treatment was $32,000.00 per QALY at the mild stage and $140,000.00</s><s>per QALY at the moderate stage of AD.</s></p><p><s>Hauber et al. <ref type="bibr" target="#b21">19</ref> estimated the potential cost savings per patient using rivastigmine for the treatment of AD in Canada.</s><s>Their research suggested that this drug may delay onset of the most severe stage of AD for up to 188 days in patients with mild AD after 2 years of treatment.</s><s>For patients with mild-to-moderate and moderate AD, the estimated delays were 106 and 44 days, respectively.</s></p><p><s>The mean cost saved per patient was $0.45 per day at 6 months and $6.44 per patient after 2 years for mild AD.</s><s>Although these results are promising, there is uncertainty about the cost-effectiveness of rivastigmine because data on the natural history of disease were not available in the study, making interpretation difficult.</s><s>In a systematic review, Loveman et al. <ref type="bibr" target="#b49">44</ref> evaluated cost-effectiveness studies of pharmacological treatments for AD.</s><s>Four economic evaluations of rivastigmine, all sponsored by pharmaceutical industries, were analyzed.</s><s>According to the review, reducing treatment costs does not offset the treatment cost with rivastigmine enough for it to be considered cost-effective at levels acceptable to the UK National Health Service (od50,000 per QALY).</s></p><p><s>The present study has several limitations that merit discussion.</s><s>Some are inherent to the modeling process, which might oversimplify the process of disease progression because of its divergence from real-world circumstances.</s><s>In addition, international data were used, given the scarcity of information about AD in the Brazilian context.</s><s>8]<ref type="bibr" target="#b21">[19]</ref><ref type="bibr" target="#b22">[20]</ref><ref type="bibr" target="#b23">[21]</ref><ref type="bibr" target="#b24">[22]</ref><ref type="bibr" target="#b25">[23]</ref> The differences between these probabilities may be related to the timing of publication of the original studies; other values might have modified the results of our simulation.</s><s>The cost of institutionalization was not included in the model due to the scarcity of such information.</s><s>Finally, the social costs involved in the treatment of AD, which, according to the literature, account for a large part of disease-related costs, <ref type="bibr" target="#b50">45</ref> were not considered, despite their potential impact on the cost-effectiveness analysis.</s></p><p><s>Finally, it is worth noting that economic health assessments are not intended to exhaust all existing technological alternatives.</s><s>The analysis performed herein, for example, included the alternatives most prevalent in the SUS.</s><s>Thus, we did not consider use of the anticholinesterase agent galantamine, which is also approved and dispensed in the SUS for mild to moderate AD, nor of the 12-mg dose of rivastigmine, due to its restricted use in the public sector.</s></p><p><s>In conclusion, this is one of the first cost-effectiveness studies of AD treatment in the mild and moderate stages and, to our knowledge, is the first to use a Markov model.</s><s>No Brazilian studies had ever estimated the costs of diagnosis, follow-up, and treatment of AD.</s></p><p><s>The purpose of pharmacological treatment is to treat symptoms and slow the progression of AD, thereby reducing its burden on society and postponing the carerelated expenditures that accompany the more advanced stages of the disease.</s><s>From this perspective, our findings suggest that donepezil is the most cost-effective option for the SUS.</s><s>In this sense, current practice in Brazil represents a worst-case scenario.</s><s>The most common pharmacological treatment option, based on treatment with rivastigmine, has a lower effectiveness (0.39 QALYs/ BRL 32,685.77)</s><s>than donepezil.</s></p><p><s>Probabilistic analysis indicates that donepezil is the most cost-effective treatment for mild and moderate AD.</s><s>The results of this study can help inform political decisions to establish the best treatment strategy for AD in its initial and moderate stages, as well as suggest pathways to a comprehensive policy for dementia care in Brazil.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Schematic representation of the disease stages of the simulation model.</s><s>AD = Alzheimer's disease.</s></p></div></figDesc><graphic coords="2,133.63,526.05,308.64,192.30" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Monte Carlo cost-effectiveness analysis of donepezil vs.rivastigmine.</s><s>WTP = willingness to pay.</s></p></div></figDesc><graphic coords="5,145.93,71.72,326.84,237.15" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Outcomes of interest incorporated into the Markov model</s></p></div></figDesc><table><row><cell>Probability</cell><cell>Mean (SD)</cell><cell>Source</cell></row><row><cell>Natural history of AD Death during the mild stage</cell><cell>0.038 (0.024)</cell><cell>Morris et al. 23 and Spackman et al. 18</cell></row><row><cell>Death during the moderate stage</cell><cell>0.134 (0.081)</cell><cell></cell></row><row><cell>Stable-mild stage</cell><cell>0.694 (0.113)</cell><cell></cell></row><row><cell>Moderate-mild stage</cell><cell>0.057 (0.014)</cell><cell></cell></row><row><cell>Severe-mild stage</cell><cell>0.001 (0.001)</cell><cell></cell></row><row><cell>Death during the severe stage</cell><cell>0.317 (0.164)</cell><cell></cell></row><row><cell>Mild-moderate stage</cell><cell>0.240 (0.116)</cell><cell></cell></row><row><cell>Mild-severe stage</cell><cell>0.028 (0.021)</cell><cell></cell></row><row><cell>Stable-moderate stage</cell><cell>0.533 (0.032)</cell><cell></cell></row><row><cell>Moderate-severe stage</cell><cell>0.227 (0.062)</cell><cell></cell></row><row><cell>Severe-moderate stage</cell><cell>0.014 (0.014)</cell><cell></cell></row><row><cell>Stable-severe stage</cell><cell>0.670 (0.178)</cell><cell></cell></row><row><cell>Rivastigmine Mild stage</cell><cell>0.724 (0.110)</cell><cell>Fenn &amp; Gray 20 and Hauber et al. 19</cell></row><row><cell>Moderate stage</cell><cell>0.274 (0.231)</cell><cell></cell></row><row><cell>Severe stage</cell><cell>0.070 (0.071)</cell><cell></cell></row><row><cell>Death during the mild stage</cell><cell>0.038 (0.024)</cell><cell></cell></row><row><cell>Death during the moderate stage</cell><cell>0.134 (0.115)</cell><cell></cell></row><row><cell>Death during the severe stage</cell><cell>0.316 (0.241)</cell><cell></cell></row><row><cell>Donepezil Stable-mild stage Mild-moderate stage</cell><cell>0.668 (0.092) 0.210 (0.097)</cell><cell>Stewart et al., 24 Neumann et al., 22 Jonsson et al., 21 and Ikeda et al. 17</cell></row><row><cell>Mild-severe stage</cell><cell>0.018 (0.022)</cell><cell></cell></row><row><cell>Death during the mild stage</cell><cell>0.038 (0.024)</cell><cell></cell></row><row><cell>Stable-moderate stage</cell><cell>0.560 (0.057)</cell><cell></cell></row><row><cell>Moderate-severe stage</cell><cell>0.261 (0.068)</cell><cell></cell></row><row><cell>Death during the moderate stage</cell><cell>0.134 (0.115)</cell><cell></cell></row><row><cell>Moderate-mild stage</cell><cell>0.089 (0.058)</cell><cell></cell></row><row><cell>Severe-mild stage</cell><cell>0.001 (0.001)</cell><cell></cell></row><row><cell>Severe-moderate stage</cell><cell>0.014 (0.014)</cell><cell></cell></row><row><cell>Stable-severe stage</cell><cell>0.835 (0.208)</cell><cell></cell></row><row><cell>Death during severe stage</cell><cell>0.085 (0.231)</cell><cell></cell></row><row><cell>Utility 4</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2</head><label>2</label><figDesc><div><p><s>Cost of the pharmacological treatment of selected outcomes, in Brazilian reais (BRL)</s></p></div></figDesc><table><row><cell>Description</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 3</head><label>3</label><figDesc><div><p><s>Cost analysis of the selected Alzheimer's disease treatment scenarios</s></p></div></figDesc><table><row><cell>Comparison strategy</cell><cell>Annual cost (BRL)</cell><cell>Effectiveness</cell><cell>Incremental cost (BRL)</cell><cell>Incremental effectiveness</cell><cell>ICER</cell></row><row><cell>Natural history</cell><cell>28,080.13</cell><cell>3.52</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Donepezil</cell><cell>30,556.45</cell><cell>4.26</cell><cell>2,476.32</cell><cell>0.741</cell><cell>3,342.13</cell></row><row><cell>Rivastigmine</cell><cell>32,685.77</cell><cell>3.87</cell><cell>-</cell><cell>-</cell><cell>(Dominated)</cell></row></table><note><p><s>BRL = Brazilian reais; ICER = incremental cost-effectiveness ratio.</s><s>Braz J Psychiatry. 2019;41(3) Cost-effective Alzheimer's treatment increase of 0.58/BRL 24,683.33 for patients treated with rivastigmine in the mild stage; in the moderate stage, the increases observed were 0.05 QALY/BRL 27,414.96</s><s>for patients treated with donepezil and 0.06 QALY/BRL 34,222.96</s><s>for patients treated with rivastigmine.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">LR da Silva et al.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>This study was financed in part by Coordenac ¸a ˜o de Aperfeic ¸oamento de Pessoal de Nı ´vel Superior (CAPES; grant 001).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure</head><p><s>VM has received grants from Novartis, Wyeth, EMS, Janssen-Cilag, Apsen Farmace ˆutica, Ache ´, Lundbeck, Lilly, moksha8, and Servier.</s><s>JL has received grants from Novartis, Wyeth, EMS, Janssen-Cilag, Apsen Farmace ˆutica, Ache ´, Lundbeck, Lilly, moksha8, and Servier.</s><s>The other authors report no conflicts of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Epidemiology of Alzheimer&apos;s disease: occurrence, determinants, and strategies toward intervention</title>
		<author>
			<persName><forename type="first">C</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kivipelto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Strauss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dialogues Clin Neurosci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="111" to="128" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">World Health Organization/Alzheimer&apos;s Disease International (WHO/ ADI)</title>
		<imprint>
			<date type="published" when="2012">2012. 2018</date>
		</imprint>
	</monogr>
	<note>Dementia: a public health priority. Internet. cited</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Prevalence of dementia subtypes in a developing country: a clinicopathological study</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Grinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nitrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Suemoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lucena</forename><surname>Ferretti-Rebustini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Leite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Farfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinics (Sa ˜o Paulo)</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1140" to="1145" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Prevalence of dementia in Latin America: a collaborative study of population-based cohorts</title>
		<author>
			<persName><forename type="first">R</forename><surname>Nitrini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bottino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Albala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Custodio</forename><surname>Capun ˜ay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Ketznoian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Libre</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Psychogeriatr</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="622" to="630" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Diagno ´stico clı ´nico na doenc¸a de Alzheimer. Rio de Janeiro: Guanabara Koogan</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bottino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Laks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Blay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Machado JCB</title>
				<imprint>
			<date type="published" when="2006">2006</date>
			<biblScope unit="page" from="173" to="176" />
		</imprint>
	</monogr>
	<note>Deme ˆncia e transtornos cognitivos em idosos</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Incidence of dementia and cause of death in elderly Japanese emigrants to Brazil before World War II</title>
		<author>
			<persName><forename type="first">K</forename><surname>Meguro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Y</forename><surname>Chubaci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Meguro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kawamorida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Caramelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Gerontol Geriatr</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="75" to="78" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Incidence of mild cognitive impairment and Alzheimer disease in Southern Brazil</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Chaves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Camozzato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Godinho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Piazenski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Geriatr Psychiatry Neurol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="181" to="187" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">N</forename><surname>Bergvall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Brinck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gustavsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Winblad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int Psychogeriatr</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="73" to="85" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">The acquisition of medication to treat Alzheimer&apos;s disease in Brazil: an analysis of federal purchases</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Da Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Osorio-De-Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Da Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maia</forename><surname>Ada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Ramos</forename><surname>Mde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Caetano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008-2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Colet</forename><surname>Cienc Saude</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="3827" to="3838" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Alzheimer&apos;s Disease International (ADI)</title>
		<ptr target="www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf" />
		<imprint>
			<date type="published" when="2010-09-21">2010. 2010 Sep 21. 2018 May 23</date>
		</imprint>
	</monogr>
	<note>The Global Economic Impact of Dementia. Internet</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Portaria n o 843, de 31 de outubro de 2002. Aprova o Protocolo Clı ´nico e Diretrizes Terape ˆuticas da Doenc¸a de Alzheimer</title>
		<author>
			<persName><forename type="first">Ministe</forename><surname>Brasil</surname></persName>
		</author>
		<author>
			<persName><surname>Da Sau ´de</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Dia ´rio Oficial da Unia ˜o, 4 novembro 2013</title>
		<ptr target="www.lex.com.br/doc_5930363_PORTARIA_N_843_DE_31_DE_OUTUBRO_DE_2002.aspx" />
		<imprint>
			<date type="published" when="2018-05-24">2018 May 24</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Efica ´cia do tratamento farmacolo ´gico da deme ˆncia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Flicker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Bras Psiquiatr</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="11" to="14" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Neuropsychopharmacology: the fifth generation of progress</title>
		<author>
			<persName><forename type="first">A</forename><surname>Manca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A ;</forename><surname>Buerns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Charney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Coyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nemeroff</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2002">2002</date>
			<publisher>Lippincott</publisher>
			<biblScope unit="page" from="1267" to="1279" />
			<pubPlace>Williams, &amp; Wilkins</pubPlace>
		</imprint>
	</monogr>
	<note type="report_type">Philadelphia</note>
	<note>Cost-effectiveness of therapeutics for Alzheimer disease</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Gastos com medicamentos para tratamento da Doenc¸a de Alzheimer pelo Ministe ´rio da Sau ´de</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Lima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">O</forename><surname>Coradi</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2007">2007-2011</date>
		</imprint>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title level="m" type="main">Access to medicines for Alzheimer&apos;s disease provided by the Brazilian Unified National Health System in Minas Gerais State</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Almeida-Brasil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Costa</forename><surname>Jde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Aguiar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Moraes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Acurcio</forename><surname>Fde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<imprint>
			<pubPlace>Brazil</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Cad Saude Publica</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page">e00060615</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Mini-mental state&apos;&apos;. A practical method for grading the cognitive state of patients for the clinician</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Folstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Folstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Mchugh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Psychiatr Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="189" to="198" />
			<date type="published" when="1975">1975</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Economic evaluation of donepezil treatment for Alzheimer&apos;s disease in Japan</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ikeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ikegami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dement Geriatr Cogn Disord</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="33" to="39" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Spackman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kadiyala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Veenstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Sullivan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Alzheimer Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1050" to="1058" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Savings in the cost of caring for patients with Alzheimer&apos;s disease in Canada: an analysis of treatment with rivastigmine</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Hauber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gnanasakthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mauskopf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="439" to="451" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Estimating long-term cost savings from treatment of Alzheimer&apos;s disease. A modelling approach</title>
		<author>
			<persName><forename type="first">P</forename><surname>Fenn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacoeconomics</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="165" to="174" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">The costeffectiveness of donepezil therapy in Swedish patients with Alzheimer&apos;s disease: a Markov model</title>
		<author>
			<persName><forename type="first">L</forename><surname>Jonsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lindgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jonsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Winblad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Ther</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1230" to="1240" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Neumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Hermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Kuntz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Araki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Duff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Leon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="1138" to="1145" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">The consortium to establish a registry for Alzheimer&apos;s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Heyman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Mohs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Van Belle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fillenbaum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="1159" to="1165" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Pharmacotherapy for people with Alzheimer&apos;s disease: a Markov-cycle evaluation of five years&apos; therapy using donepezil</title>
		<author>
			<persName><forename type="first">A</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dempsey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Geriatr Psychiatry</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="445" to="453" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The prevalence and the course of neuropsychiatric symptoms in patients with dementia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bergh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Selbaek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nor Epidemiol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="225" to="232" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Tratando os sintomas comportamentais e psicolo ´gicos da deme ˆncia (SCPD)</title>
		<author>
			<persName><forename type="first">P</forename><surname>Camelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cmc</forename><surname>Bottino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Bras Psiquiatr</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="83" to="87" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Frontal functions in depressed and nondepressed</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Silberman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Laks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Capita ˜o</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Rodrigues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Vasconcellos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Braz J Psychiatry</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">3</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<monogr>
		<title level="m" type="main">Cost-effective Alzheimer&apos;s treatment</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Parkinson&apos;s disease patients: impact of severity stages</title>
	</analytic>
	<monogr>
		<title level="j">Psychiatry Res</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="285" to="289" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Risk factors for neuropsychiatric symptoms in dementia: the cache county study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Steinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Corcoran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Tschanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Welsh-Bohmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Norton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Geriatr Psychiatry</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="824" to="830" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a communitybased sample in Brazil: prevalence and relationship with dementia severity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Tatsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bottino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Azevedo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Hototian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Moscoso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Folquitto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Geriatr Psychiatry</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="438" to="445" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Aalten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Vugr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Jaspers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jolles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Verthey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Geriatr Psychiatry</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="523" to="530" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Pharmacological treatment of neuropsychiatric symptoms in Alzheimer&apos;s disease: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">F</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Tan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="101" to="109" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Burden of Alzheimer&apos;s disease and association with negative health outcomes</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Malone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Mclaughlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Wahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leibman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Arrighi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Cziraky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Manag Care</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="481" to="488" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">A multifactorial intervention to reduce the risk of falling among elderly people living in the community</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Tinetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">I</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mcavay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Claus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Garrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gottschalk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">331</biblScope>
			<biblScope unit="page" from="821" to="827" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Fatores associados ao custo das internac¸o ˜es hospitalares por doenc¸as infecciosas em idosos em hospital de refere ˆncia na cidade do Natal</title>
		<author>
			<persName><forename type="first">G</forename><surname>Piuvezam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Freitas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Freitas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pmo</forename><surname>Cardoso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Acm</forename><surname>Medeiros</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cad Saude Colet</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="63" to="68" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Oremus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Tarride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Clayton</forename><forename type="middle">N</forename><surname>Raina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Canadian Willingness-to-Pay Study Group, Raina P. Health utility scores in Alzheimer&apos;s disease: differences based on calculation with American and Canadian preference weights</title>
	</analytic>
	<monogr>
		<title level="j">Value Health</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="77" to="83" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Cross sectional observational study on the societal costs of Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mesterton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>By</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Langworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Winblad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jonsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Alzheimer Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="358" to="367" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Patient-and proxy-reported utility in Alzheimer disease using the EuroQoL</title>
		<author>
			<persName><forename type="first">L</forename><surname>Jonsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Andreasen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Kilander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Soininen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Waldemar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nygaard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alzheimer Dis Assoc Disord</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="49" to="55" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Utility-based quality of life measures in Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">G</forename><surname>Naglie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tomlinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tansey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Irvine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ritvo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Black</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="631" to="643" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer&apos;s disease in Germany using discrete event simulation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Getsios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Blume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maclaine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Neurol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">2</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title level="m" type="main">Departamento de Informa ´tica do Sistema U ´nico de Sau ´de (DATASUS)</title>
		<author>
			<persName><surname>Brasil</surname></persName>
		</author>
		<ptr target="sigtap.datasus.gov.br/" />
		<imprint>
			<date type="published" when="2016-04-14">2016 Apr 14</date>
		</imprint>
	</monogr>
	<note>Medicamentos e OPM do SUS. Internet</note>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<title level="m" type="main">Portal de compras do Governo Federal</title>
		<author>
			<persName><surname>Brasil</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>Internet. cited</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Tecnologia e Insumos Estrate ´gicos, Departamento de Cie ˆncia e Tecnologia. Diretrizes metodolo ´gicas, diretriz de avaliac¸a ˜o econo ˆmica</title>
		<author>
			<persName><forename type="first">Ministe</forename><surname>Brasil</surname></persName>
		</author>
		<author>
			<persName><surname>Da Sau ´de</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Secretaria de Cie ˆncia</title>
				<imprint/>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Cost-effectiveness thresholds: pros and cons</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Bertram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>De Joncheere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Edejer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hutubessy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Kieny</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bull World Health Organ</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="925" to="930" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Loveman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kirby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Takeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Picot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Payne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Health Technol Assess</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="1" to="160" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">An economic evaluation of donepezil in mild to moderate Alzheimer&apos;s disease: results of a 1-year, double-blind, randomized trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Wimo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Winblad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Engedal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Soininen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Verhey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Waldemar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dement Geriatr Cogn Disord</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="44" to="54" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
